Proactive Investors - Run By Investors For Investors

Sareum notes decision by Sierra Oncology to explore options for future development of SRA737

SRA737 is a checkpoint kinase 1 that Sierra licensed from Sareum back in 2016
test tubes in laboratory
Sierra is focussing its resources on its lead drug, momelotinib

Sierra Oncology is exploring non-dilutive strategic options to support the continued development of its portfolio of DNA damage response (DDR) assets, including SRA737.

SRA737, which is a checkpoint kinase 1 (Chk1) inhibitor, was originally discovered by Sareum Holdings PLC (LON:SAR) before Sierra licensed it back in 2016.

READ: Sareum raises £680k to fund development of its TYK2/JAK1 inhibitors

Chk1 controls a cancer cell's response to DNA damage, which could be caused by the disease itself or intentionally caused by chemotherapy or radiotherapy.

Sierra is currently using SRA737 in in two mid-stage ovarian cancer studies: one as a monotherapy and another in combination with low-dose gemcitabine – one of the most commonly-prescribed chemotherapies.

Data so far has been promising, but Sierra is focusing its resources on the development of momelotinib – its flagship drug that is being developed as a treatment for myelofibrosis.

SRA737 has shown its potential

“The clinical results presented with SRA737 at ASCO and the identification of a route to market in a cancer indication with high unmet need, together with preclinical work highlighting it in combination with other leading therapeutic modalities, clearly demonstrate the value that could be created through the further development of SRA737,” said Sareum chief executive Tim Mitchell.

“We are confident that these qualities of SRA737, based on the excellent work done to date, will be recognised and that Sierra will be successful in securing the strategic options it is seeking.”

Sierra CEO, Nick Glover, added: “While we continue to advance the assets in our DDR portfolio and view them as promising oncology drug candidates that warrant further development, we are prioritizing our resources on our lead drug, momelotinib.”

Sareum shares were down 2.2% to 0.42p on Thursday afternoon.

View full SAR profile View Profile

Sareum Holdings PLC Timeline

Related Articles

cancerous cells
April 15 2019
The company’s cancer treatment is based on work undertaken by John Beard, a professor of embryology at Edinburgh University nearly 100 years ago
A stomach adenocarcinoma
February 13 2019
The company’s B-cell peptide cancer vaccines have shown promise in pre-clinical and early-stage study.
lung x-ray
May 07 2019
The company has been developing a treatment for chronic lung disease in-house and has partnered with an Australian group to develop a drug for rare liver and lung complaints

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use